19.45 USD
+0.26 (+1.35%)
19.45 USD
0 (0%)
Taking everything into account, CDNA scores 6 out of 10 in our fundamental rating. CDNA was compared to 530 industry peers in the Biotechnology industry. While CDNA has a great health rating, its profitability is only average at the moment. CDNA is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
CDNA had positive earnings in the past year.
CDNA had a positive operating cash flow in the past year.
In the past 5 years CDNA reported 4 times negative net income.
In multiple years CDNA reported negative operating cash flow during the last 5 years.
1.2 Ratios
CDNA's Return On Assets of 14.06% is amongst the best of the industry. CDNA outperforms 94.92% of its industry peers.
CDNA has a better Return On Equity (19.53%) than 95.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CDNA (16.97%) is better than 92.86% of its industry peers.
With an excellent Gross Margin value of 67.62%, CDNA belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
In the last couple of years the Gross Margin of CDNA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDNA has more shares outstanding than it did 1 year ago.
CDNA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CDNA has an Altman-Z score of 3.73. This indicates that CDNA is financially healthy and has little risk of bankruptcy at the moment.
CDNA's Altman-Z score of 3.73 is fine compared to the rest of the industry. CDNA outperforms 70.30% of its industry peers.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.73 |
ROIC/WACCN/A
WACC8.8%
2.3 Liquidity
CDNA has a Current Ratio of 3.03. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.03, CDNA is not doing good in the industry: 64.10% of the companies in the same industry are doing better.
CDNA has a Quick Ratio of 2.75. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA has a worse Quick ratio (2.75) than 66.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.11% over the past year.
CDNA shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 37.47% yearly.
CDNA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.46%.
CDNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.30% yearly.
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
3.2 Future
Based on estimates for the next years, CDNA will show a very strong growth in Earnings Per Share. The EPS will grow by 38.18% on average per year.
Based on estimates for the next years, CDNA will show a quite strong growth in Revenue. The Revenue will grow by 13.01% on average per year.
EPS Next Y25.04%
EPS Next 2Y30.7%
EPS Next 3Y33.39%
EPS Next 5Y38.18%
Revenue Next Year12.7%
Revenue Next 2Y12.35%
Revenue Next 3Y11.91%
Revenue Next 5Y13.01%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CDNA is valuated quite expensively with a Price/Earnings ratio of 29.92.
Compared to the rest of the industry, the Price/Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 92.67% of the companies listed in the same industry.
CDNA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.39, which is the current average of the S&P500 Index.
CDNA is valuated rather expensively with a Price/Forward Earnings ratio of 21.08.
93.98% of the companies in the same industry are more expensive than CDNA, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, CDNA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.92 | ||
| Fwd PE | 21.08 |
4.2 Price Multiples
93.98% of the companies in the same industry are more expensive than CDNA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.47 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDNA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CDNA's earnings are expected to grow with 33.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.19
PEG (5Y)0.8
EPS Next 2Y30.7%
EPS Next 3Y33.39%
5. Dividend
5.1 Amount
CDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
19.45
+0.26 (+1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.08%
Inst Owner Change-1.66%
Ins Owners2.49%
Ins Owner Change0.65%
Market Cap1.00B
Revenue(TTM)358.00M
Net Income(TTM)60.76M
Analysts80
Price Target23.46 (20.62%)
Short Float %13.29%
Short Ratio6.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.85%
Min EPS beat(2)-18.08%
Max EPS beat(2)93.77%
EPS beat(4)3
Avg EPS beat(4)37.25%
Min EPS beat(4)-18.08%
Max EPS beat(4)93.77%
EPS beat(8)7
Avg EPS beat(8)226.86%
EPS beat(12)11
Avg EPS beat(12)161.16%
EPS beat(16)12
Avg EPS beat(16)102.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)2.98%
Revenue beat(4)2
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)2.98%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)8
Avg Revenue beat(12)5.96%
Revenue beat(16)8
Avg Revenue beat(16)3.77%
PT rev (1m)2.22%
PT rev (3m)2.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.9%
EPS NY rev (1m)23.74%
EPS NY rev (3m)18.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.92 | ||
| Fwd PE | 21.08 | ||
| P/S | 2.79 | ||
| P/FCF | 27.47 | ||
| P/OCF | 23.5 | ||
| P/B | 3.21 | ||
| P/tB | 4.21 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.65
EY3.34%
EPS(NY)0.92
Fwd EY4.74%
FCF(TTM)0.71
FCFY3.64%
OCF(TTM)0.83
OCFY4.25%
SpS6.96
BVpS6.05
TBVpS4.62
PEG (NY)1.19
PEG (5Y)0.8
Graham Number9.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% | ||
| FCFM | 10.17% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.35% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 59.94% | ||
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 3.73 |
F-Score7
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
EPS Next Y25.04%
EPS Next 2Y30.7%
EPS Next 3Y33.39%
EPS Next 5Y38.18%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
Revenue Next Year12.7%
Revenue Next 2Y12.35%
Revenue Next 3Y11.91%
Revenue Next 5Y13.01%
EBIT growth 1Y37.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year156.58%
EBIT Next 3Y73.54%
EBIT Next 5Y67.07%
FCF growth 1Y364.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1603.82%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDNA.
Can you provide the valuation status for CAREDX INC?
ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What is the valuation of CAREDX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 29.92 and the Price/Book (PB) ratio is 3.21.